Clinical Trial Detail

NCT ID NCT01708941
Title Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

melanoma

Therapies

Interferon alpha-2b

Ipilimumab

Age Groups: adult

No variant requirements are available.